

## Australia brings anti-COVID nasal spray Viraleze to India

11 June 2021 | News

The spray can be stored at room temperature and does not require cold storage or specialised transportation	The spray car	n be stored at room	temperature and c	does not require co	ld storage or s	specialised trans	portation
---	---------------	---------------------	-------------------	---------------------	-----------------	-------------------	-----------

India's vast population now has access to the Australian developed anti-COVID nasal spray Viraleze<sup>™</sup> following its registration in the country.

Developed by biopharmaceutical company Starpharma, Viraleze<sup>TM</sup> has shown to inactivate a broad-spectrum of respiratory viruses, including more than 99.9% of coronavirus SARS-CoV-2 (the virus that causes COVID-19). The product can be applied either before or after exposure and can be used in high-risk or crowded environments up to four times a day.

Importantly for a largely rural population like India's, the spray can be stored at room temperature and does not require cold storage or specialised transportation.

Indian consumers can purchase the spray from <a href="www.viraleze.co">www.viraleze.co</a> and Starpharma's discussions with commercial partners in India for distribution into both the private (consumer) and Government markets are well advanced.

Viraleze™ first launched in the UK at LloydsPharmacy in March and was the biggest selling product ever at LloydsPharmacy.com. It launched in Europe in early May.